Scienion company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

scienion.com

Investors Count

9

Deal Terms

1

Scienion Funding, Scienion Valuation & Scienion Revenue

2 Fundings

Scienion's latest funding round was a Acquired for on August 20, 2020.

Scienion's latest post-money valuation is from August 2020.

Sign up for a free trial to see Scienion's valuations in August 2020 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

8/20/2020

Acquired

$99M

0

FY undefined

1

Other Investors

0

FY undefined

0

Date

8/20/2020

Round

Acquired

Other Investors

Amount

Investors

Valuation

$99M

Revenue

0

FY undefined

0

FY undefined

Sources

1

0

Scienion Deal Terms

1 Deal Term

Scienion's deal structure is available for 1 funding round, including their Acquired from August 20, 2020.

Round

Acquired

Funding Date

$99M

Pre-Money Valuation

Post-Money Valuation

$99M

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

$99M

$99M

$99M

$99M

Scienion Investors

9 Investors

Scienion has 9 investors. BICO invested in Scienion's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

8/20/2020

8/20/2020

1
Acquired

Corporation

Sweden

3i Group

Subscribe to see more

Private Equity

United Kingdom

Peppermint VenturePartners

Subscribe to see more

Corporate Venture

Germany

S-Venture Capital Dortmund

Subscribe to see more

Venture Capital

Germany

IBB Beteiligungsgesellschaft

Subscribe to see more

Venture Capital

Germany

First funding

8/20/2020

Last Funding

8/20/2020

Investor

3i Group

Peppermint VenturePartners

S-Venture Capital Dortmund

IBB Beteiligungsgesellschaft

Rounds

1
Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporation

Private Equity

Corporate Venture

Venture Capital

Venture Capital

Location

Sweden

United Kingdom

Germany

Germany

Germany

You May Also Like

P
Pepscan

Pepscan provides peptide-based products & services offering knowledge of peptides for drug discovery collaborations. At its end-to-end facility in Lelystad, the Netherlands, Pepscan offers a range of patented technologies, phage display capabilities, a lead-optimization array platform, and production facilities for R&D- to GMP-grade peptides, including libraries and neoantigen vaccines. Among its patents is the CLIPS technology, which locks peptides into active conformations. With its epitope mapping service platform, Pepscan also supports biotech companies in developing their antibody pipelines. The underlying protein mimicry platform delivers binding insights, even in cases where other technologies, such as linear, fall short.

N
Neuromedical Systems

Neuromedical Systems, Inc. a development stage company develops, manufactures and markets systems for computer assisted screening of pap smears and other cytological specimans. The company's product papnet testing system is used in laboratories in detection of abnormal cells on pap smears. Papnet is also used in detection of bladder and lung cancer. During the year, the company acquired New System International, Ltd. The company has international operations in Europe, Israel, Asia and Australia.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Q
Q'Array

Employing recent advances in sequencing, ASPE bead array, microarray technology, Q'Array is poised to provide a range of DNA testing, including genetic, chromosomal, biochemical, pharmacogenomics, paternity, and forensic identity testing.

C
CHALEX

Chalex Corporation's precision-made chambered McMaster counting slides are used by researchers, laboratories, nematologists and veterinary practitioners throughout the world. Made of clear durable acrylic for long-lasting use, the company's slides also feature exact volumes thanks to injection-molded accuracy which yield consistent test results compared to other slides with handmade chamber spacers. The quality of these slides make them the standard the world over.

C
CAPE Technologies

CAPE Technologies, of South Portland created a practical immunoassay-based test kits for dioxin and dioxin-like PCBs. The kits provide near real time analysis in a simple field lab, at lower cost, with less equipment, and with fewer people, than conventional methods. CAPE's dioxin kit is the only rapid dioxin screening method accepted by the U.S. Environmental Protection Agency (EPA) for solid waste analysis. A third kit is also available for rapid field analysis of total PCBs. CAPE's kits are marketed by distributors in Australia, Japan, Italy, Taiwan, China, and Finland, and directly through its web site to the rest of the world. CAPE Technologies maintains local ties with the University of New England, the University of Southern Maine, and the University of Maine at Orono. Dr. Robert Harrison of Cape Elizabeth is co-founder and president.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.